Cargando…

Reclassifying ovarian cancer: origins, subtypes and resistance to therapy

Detalles Bibliográficos
Autor principal:	Bowtell, DDL
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327254/ http://dx.doi.org/10.1186/1897-4287-10-S2-A35

Ejemplares similares

The Australian Ovarian Cancer Study
por: Traficante, N, et al.
Publicado: (2012)

Primary treatment patterns in women recruited to the Australian Ovarian Cancer Study
por: Hung, J, et al.
Publicado: (2012)

Reclassifying tumour cell cycle activity in terms of its tissue of origin
por: Lundberg, Arian, et al.
Publicado: (2022)

The experiences of research participants offered genetic test results as a result of taking part in a population based ovarian cancer research study?
por: Young, MA, et al.
Publicado: (2012)

Reclassifying stroke lesion anatomy
por: Bonkhoff, Anna K., et al.
Publicado: (2021)

Codeine-containing medicines to be reclassified in NZ
Publicado: (2020)

Pathological diagnosis of ovarian cancer
por: High, Hilda, et al.
Publicado: (2012)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

Characterization of ROS Metabolic Equilibrium Reclassifies Pan-Cancer Samples and Guides Pathway Targeting Therapy
por: Shen, Shuai, et al.
Publicado: (2020)

Need to reclassify keratocystic odontogenic tumor into cyst and neoplasm
por: Singh, Harkanwal Preet
Publicado: (2016)

How genomics reclassifies diseases: the case of Alport syndrome
por: Torra, Roser, et al.
Publicado: (2020)

Reclassifying contraceptives as over-the-counter medicines to improve access
por: Ammerdorffer, Anne, et al.
Publicado: (2022)

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients
por: Thompson, ER, et al.
Publicado: (2012)

Selenium (Se) and the risk of breast, ovarian and prostate cancers
por: Jaworska, Katarzyna, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Copper transport system and response to ovarian cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Cancer predisposing BARD1 mutations in breast-ovarian cancer families
por: Ratajska, Magdalena, et al.
Publicado: (2012)

Malignant pheochromocytoma with negative biochemical markers: Is it time to reclassify pheochromocytomas?
por: Borzouei, Shiva, et al.
Publicado: (2019)

Commentary: Descending necrotizing mediastinitis: Reclassifying a rare disease
por: Bajpai, Swara, et al.
Publicado: (2021)

Update on rare variants in inherited arrhythmogenic syndromes: when to reclassify?
por: Martinez Barrios, E, et al.
Publicado: (2023)

Are We Ready to Reclassify Crohn’s Disease Using Molecular Classification?
por: Kamal, Shahed, et al.
Publicado: (2023)

Understanding subtype-selective allosteric modulation of GABA(A) receptors
por: Puthenkalam, Roshan, et al.
Publicado: (2012)

PW01-016 – Are different disease subtypes present in FMF
por: Akar, S, et al.
Publicado: (2013)

Integrated genomic analysis and functional characterisation of novel oncogenes in ovarian cancer
por: Davis, SJ, et al.
Publicado: (2012)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Antiepileptic activity and subtype-selective action of flupirtine at GABA(A) receptors
por: Bajrić, Mirnes, et al.
Publicado: (2012)

Clinical subtype of HAM/TSP based on clinical course and laboratory findings
por: Yamano, Yoshihisa, et al.
Publicado: (2011)

Functional polymorphisms in the TERT promoter are associated with risk of serious ovarian and breast cancer
por: Beesley, Jonathan, et al.
Publicado: (2012)

Early experience in a breast and ovarian cancer risk management clinic in Malaysia
por: Taib, NA, et al.
Publicado: (2012)

Risk-reducing surgery for breast and ovarian cancer risks - where are we now?
por: Hallowell, N, et al.
Publicado: (2012)

Soluble osteopontin concentrations in serum and ascites of women with advanced serous ovarian cancer
por: Černe, Katarina, et al.
Publicado: (2012)

BRCA1 mutation analysis in breast and ovarian cancer families from Greece
por: Konstantopoulou, I, et al.
Publicado: (2000)

The spectrum of mutations in families with breast and ovarian cancer from the region of Saxony, Germany
por: Tomys, Michalina, et al.
Publicado: (2015)

PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B
por: Raj-Kumar, Praveen-Kumar, et al.
Publicado: (2019)

OPCML, a novel systems regulator of tyrosine kinase signaling in ovarian and other cancers
por: Gabra, H
Publicado: (2012)

I just did it for the kids: mothering in the context of living with an increased risk of ovarian cancer
por: McEwen, A
Publicado: (2012)

Identification of new genes associated with breast and ovarian cancer risk. Advances of BCAC, CIMBA and OCAC
por: Jakubowska, A, et al.
Publicado: (2011)

Extensive parent-of-origin genetic effects on fetal growth
por: Adkins, Ronald M, et al.
Publicado: (2009)

Parental alienation diagnosis. A modern and effective subtype of domestic violence, endemic in Italian courts
por: Pignotti, Maria Serenella
Publicado: (2014)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ul6j5ssjedormcnnivfl6oo0hm